biologix LABORATORIES

A Life Science Company

Companion Diagnostic Tests.
Testing solutions for precision medicine in Cancer,

Cancer Type	CDx Test name	Description	TAT	Sample Type	Price (NGN)		
LUNG CANCER	Lung Cancer Panel (Multi gene panel)	Detection of actionable mutations for Lung Cancer covering up to **167 variants (85 DNA mutations and 82 RNA Fusions) in 11 genes** -EGFR, HER2, KRAS and BRAF genes. -Gene fusions in ALK, ROS1, RET, Met exon 14 Skipping, NTRK1, NTRK2 and NTRK3 genes. The Lung Cancer Panel identifies all NCCN (National Comprehensive Cancer Network) recommended biomarkers.	10-15 working days	Formalin-fixed paraffin-embedded (FFPE) tumor tissue (with min of 30% Tumour content)	1,993,993.00		
	EGFR Mutations (Priority)	Detects up to 29 mutations in the EGFR gene including **Exon 19 deletions**, Insertions, Mutations on S768I, L861Q and/or G719X mutations, T790M, L858R	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**627,723.23**		
	RET Gene fusions	detection of up to 9 RET gene fusions in human RNA	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**Call**		
	MET exon 14 Skipping mutations	detection of *MET*exon14 skipping mutation in human RNA	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**Call**		
	EML4/ALK Fusion (2 gene panel)	detection of up to 21 *EML4-ALK* fusions in human RNA extracted from NSCLC patients	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**Call**		
	ALK and ROS1 Gene Fusions (2 gene panel)	Detects up to 14 *ALK* gene fusions and 14 *ROS1* gene fusions in human RNA	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**1,349,336.18**		

October 28th 2025

biologix LABORATORIES

A Life Science Company

Companion Diagnostic Tests.
Testing solutions for precision medicine in Cancer,

	EGFR/ROS1/ALK (3 gene panel)	Detection of up to 58 variants in *EGFR, ALK*, and *ROS1* genes in human DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue samples	TBC	FFPE tumor tissue (with min of 30% Tumour content)	**1,505,200.20**		

Cancer Type	Test name	Description	TAT	Sample Type	Price (NGN)		
Colorectal Cancer	KRAS	Detection of the main mutations of exon 2 (codons 12, 13), of exon 3 (codons 59, 61) and of exon 4 (codons 117, 146) of the gene KRAS	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**580,074.95**		
	NRAS	Detection of the main mutations of exon 2 (codons 12, 13), of exon 3 (codons 59, 61) and of exon 4 (codons 117, 146) of NRAS gene	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**580,074.95**		
	KRAS/NRAS	Detection of Mutations in both KRAS and NRAS gene	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**699,728.21**		
	MSI	Tracks variations in microsatellite lengths across eight novel biomarkers (*EIF4E3, IFT140, PPP1CC, UBAC2, PRR5-ARHGAP8, ACVR2A, TAOK3, RBM14-RBM4*) presence of MSI indicates a potential defect in the mismatch repair (dMMR) mechanisms.	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**550,046.00**		
	KRAS/NRAS/BRAF	detection of up to 31 somatic mutations of the *KRAS, NRAS*, and *BRAF* genes in human DNA extracted from formalin-fixed paraffin-ded (FFPE) tissue	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**795,889.30**		
	KRAS/NRAS/BRAF/MSI	detection of up to 70 somatic mutations of the *KRAS, NRAS*, and *BRAF* genes in human DNA extracted from formalin-fixed paraffin-ded (FFPE) tissue. Also tracks variations in MSI	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**1,080,906.30**		

October 28th 2025

biologix LABORATORIES

A Life Science Company

Companion Diagnostic Tests.
Testing solutions for precision medicine in Cancer,

Colon, lung, thyroid, melanoma, also brain, ovarian, non-Hodgkin Lyphoma	BRAF	Detection of V600E, V600K, V600E2, V600R, V600D2,V600A	7 to 10 working days	FFPE tumor tissue (with min of 30% Tumour content)	**480,822.00**		
Multi Gene Panel		Detection of up to 118 variants across 9 genes (*KRAS, NRAS, BRAF, PIK3CA, ROS1, RET, HER2, ALK* and *EGFR*). It is designed to assist in identifying clinically relevant biomarkers for patients with non-small cell lung cancer (NSCLC) who may be eligible for approved targeted therapies.	Available	FFPE tumor tissue (with min of 30% Tumour content)	1,822,714.00		
Breast Cancer	PIK3CA	Detection of 11 mutations which are the main mutations of codons 345, 420, 542, 545, 546, 1047, 1049 of the PIK3CA gene	Available	FFPE tumor tissue (with min of 30% Tumour content)	**601,507.56**		
	HER 2	Detection of up to 13 variants in human DNA extracted from formalin-fixed paraffin-ded (FFPE) tissue	Available	FFPE tumor tissue (with min of 30% Tumour content)	**601,507.56**		
Thyroid Cancer Panel	Multigene Test	Detection of mutations in 10 genes associated with Thyroid cancer	Call	FFPE tumor tissue (with min of 30% Tumour content)	1,568,302.00		
Breast/Prostrate/Ovarian NGS	BRCA 1& 2 (Germline)	Detection of mutations in BRCA 1 and 2 genes that are pathogenic and have clinical significance. BRCA Pro Panel comprehensively covers all protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes	Available	10mls Whole Blood in 2 EDTA	**936,495.00**		
	BRCA 1& 2 (Somatic)	Detection of mutations in BRCA 1 and 2 genes that are pathogenic and have clinical significance. BRCA Pro Panel comprehensively covers all protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes	Avalable	FFPE tumor tissue (with min of 30% Tumour content)	**1,070,982.75**		

October 28th 2025

Companion Diagnostic Tests.
Testing solutions for precision medicine in Cancer,

	HRR BRCA 1 & 2 and 30 plus Genes (Germline)	Detects SNVs and Large rearrangements in BRCA1, BRCA 2 genes. SNVs in genes AR, ATM, ATR, BARD1, BRIP1, CDH1, CDK12, CHEK1, CHEK2, ESR1, FANCA, FANCL, HDAC2, HOXB13, MRE11, NBN, PALB2, PP2R2A, PTEN, RAD51B, RAD51C, RAD51D, RAD54L,STK11, TP53, BRAF, ERBB2, KRAS, NRAS, PIK3CA	Available	10mls Whole Blood in 2 EDTA	**1,461,119.71**		
	HRR BRCA 1 & 2 and 30 plus Genes (Somatic	Detects SNVs and Large rearrangements in BRCA1, BRCA 2 genes. SNVs in genes AR, ATM, ATR, BARD1, BRIP1, CDH1, CDK12, CHEK1, CHEK2, ESR1, FANCA, FANCL, HDAC2, HOXB13, MRE11, NBN, PALB2, PP2R2A, PTEN, RAD51B, RAD51C, RAD51D, RAD54L,STK11, TP53, BRAF, ERBB2, KRAS, NRAS, PIK3CA	Available	FFPE tumor tissue (with min of 30% Tumour content)	**1,539,067.48**		
	HRD Focus	Detection in the Homologous recombinant repair (HRR) pathway and any Homologous recombinant deficiency (HRD). Genes in focus BRCA 1& 2	Available from Jan 2026	FFPE tumor tissue (with min of 30% Tumour content)	**TBC**		
	HRD Complete	Detects mutations in 20 Homologous recombinant repair (HRR) genes and any Homologous recombinant deficiency (HRD) ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CHEK1, CHEK2, FANCA, FANCL, HDAC2, PALB2, PPP2R2A,PTEN, RAD51B, RAD51C, RAD51D, RAD54L,TP53.	Available from Jan 2026	FFPE tumor tissue (with min of 30% Tumour content)	**TBC**		
Multi-cancer Panels	Handle Essential Panel	The assay is tailored to detect prevalent mutations in 10 genes in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), using FFPE or Liquid Biopsy samples. Mutations include CNVs. Fusions, SNV and Indels in the following genes- EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET	Available	FFPE tumor tissue (with min of 30% Tumour content)	1,808,858.77		
	Handle Classic Panel	The AmoyDx HANDLE Classic Panel encompasses 40 key solid tumor genes, enabling the detection of common mutations to support clinical therapeutic decisions with rapid turnaround time (TAT). Critical biomarkers guiding pan-cancer targeted therapy have emerged, emphasizing the importance of detecting multiple gene mutations in cancer patients	Available	FFPE tumor tissue (with min of 30% Tumour content)	2,930,479.39		

Companion Diagnostic Tests.
Testing solutions for precision medicine in Cancer,

		for precise and effective treatment. Mutations cover CNVs, Fusions, SNPs, SNV/Indels					
	Oncopro Liquid Panel	The AmoyDx ® HANDLE OncoPro NGS Panel is a qualitative NGS assay that provides comprehensive genomic profiling using both DNA and RNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The panel covers a total of 195 genes, enabling the detection of somatic single-nucleotide variants (SNV), insertions and deletions (InDel), gene fusions (on the RNA level), copy number amplifications (CNA), and homozygous deletions (HD). In addition, the panel also enables the evaluation of tumor microsatellite instability (MSI) status, homologous recombination deficiency (HRD) status, and the genetic polymorphisms of drug-metabolising enzymes in cancer chemotherapy	Available	10mls Whole Blood in 2 EDTA bottles	7,484,680.28		
Cancer Immunology	PD-L1		20-25 Working days	FFPE tumor tissue (with min of 30% Tumour content)	**Call**		
	PD-1		TBC	TBC	TBC		
Contact us for other mutations of interest.							
Kindly Note that prices are subject to change without notice							

Test Request

Send an email to Customercare@biologix.com.ng or biologixlabsng@gmail.com or call 08053072221

We will send you instructions on how to proceed with your selected test.

Thank you for Choosing Biologix

October 28th 2025

biologiq LABORATORIES

A Life Science Company

Companion Diagnostic Tests.
Testing solutions for precision medicine in Cancer,
GUIDE FOR APPROVED TARGETED THERAPIES

TUMOR TYPES	BIOMARKERS	FDA-APPROVED THERAPY
Solid Tumors	*NTRK1/2/3* fusions	Vitrakvi® (larotrectinib) or Rozlytrek® (entrectinib)
	MSI-H	Keytruda® (pembrolizumab)
	RET	Retevmo (selpercatinib)
Non-Small Cell Lung Cancer (NSCLC)	*EGFR* exon 20 T790M alterations	Tagrisso® (osimertinib)
	EGFR exon 19 deletions and *EGFR* exon 21 L858R alterations	*EGFR* Tyrosine Kinase Inhibitors (TKI) approved by FDA[1]
	EGFR exon 20 insertion mutations	EXKIVITY® (mobocertinib)
	ROS1 fusions	Rozlytrek® (entrectinib)
	MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping	Tabrecta® (capmatinib)
	ALK rearrangements	Alecensa®(alectinib), Alunbrig® (brigatinib), Xalkori® (crizotinib), or Zykadia® (ceritinib)
	BRAF V600E	Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) or BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib)
Melanoma	*BRAF* V600E	*BRAF* Inhibitors approved by FDA*
	BRAF V600E and V600K	Mekinist® (trametinib) or BRAF/MEK Inhibitor Combinations approved by FDA[1]
	BRAF V600 mutation-positive	Tecentriq® (atezolizumab) in combination with Cotellic® (cobimetinib) and Zelboraf® (vemurafenib)
Breast Cancer	*ERBB2* (HER2) amplification	Herceptin® (trastuzumab), Kadcyla® (ado-trastuzumab-emtansine), or Perjeta® (pertuzumab)
	PIK3CA C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y alterations	Piqray® (alpelisib)
Colorectal Cancer	*KRAS* wild-type (absence of mutations in codons 12 and 13)	Erbitux® (cetuximab)
	KRAS wild-type (absence of mutations in exons 2, 3 and 4) and *NRAS* wild-type (absence of mutations in exons 2, 3 and 4)	Vectibix® (panitumumab)
	BRAF V600E	BRAFTOVI® (encorafenib) in combination with cetuximab
Ovarian Cancer	*BRCA1/2* alterations	Lynparza® (olaparib)
Cholangiocarcinoma	*FGFR2* fusions and select rearrangements	Pemazyre™ (pemigatinib) or Truseltiq™ (infigratinib)
Prostate Cancer	Homologous Recombination Repair (*HRR*) gene (*BRCA1*, *BRCA2*, *ATM*, *BARD1*, *BRIP1*, *CDK12*, *CHEK1*, *CHEK2*, *FANCL*, *PALB2*, *RAD51B*, *RAD51C*, *RAD51D* and *RAD54L*) alterations	Lynparza® (olaparib)
	BRCA1/2 alterations	Rubraca® (rucaparib) or AKEEGATM (niraparib and abiraterone acetate dual action tablet)

October 28th 2025